Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increase in the prevalence of chronic conditions
3.2.1.2 Advancements in immunoassay technologies
3.2.1.3 Growing demand for point-of-care testing
3.2.1.4 Rising awareness and screening programs
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory framework
3.2.2.2 Challenges associated with immunoassay
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Reagents & kits
5.2.1 ELISA reagents & kits
5.2.2 ELISPOT reagents & kits
5.2.3 Rapid test reagents & kits
5.2.4 Western blot reagents & kits
5.2.5 Chemiluminescence immunoassay reagents & kits
5.2.6 Immunofluorescence assay reagents & kits
5.2.7 Other reagents & kits
5.3 Analyzers/Instruments
5.3.1 Open ended systems
5.3.2 Closed ended systems
Chapter 6 Market Estimates and Forecast, By Technology, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Enzyme-linked immunosorbent assay (ELISA)
6.3 Chemiluminescence immunoassay (CLIA)
6.4 Radioimmunoassay (RIA)
6.5 Immunofluorescence assay (IFA)
6.6 Western blotting
6.7 ELISpot
6.8 Other technologies
Chapter 7 Market Estimates and Forecast, By Specimen, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Blood
7.3 Saliva
7.4 Urine
7.5 Other specimens
Chapter 8 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Infectious diseases
8.3 Oncology
8.4 Endocrinology
8.5 Cardiology
8.6 Autoimmune diseases
8.7 Therapeutic drug monitoring
8.8 Other applications
Chapter 9 Market Estimates and Forecast, By End-use, 2018-2032 ($ Mn)
9.1 Key trends
9.2 Hospitals and clinics
9.3 Diagnostic centers
9.4 Research and academic laboratories
9.5 Homecare settings
9.6 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Abbott Laboratories
11.2 Agilent Technologies, Inc.
11.3 Becton Dickinson and Company
11.4 Bio-Rad Laboratories, Inc.
11.5 Danaher Corporation
11.6 F. Hoffmann-La Roche AG
11.7 Hologic Inc.
11.8 Luminex Corporation
11.9 PerkinElmer, Inc.
11.10 QIAGEN
11.11 Sysmex Corporation
11.12 Thermo Fisher Scientific Inc.
